Skip to main content
The BMJ logoLink to The BMJ
letter
. 1994 Jun 4;308(6942):1506–1507.

Tacrine and lecithin in Alzheimer's disease. Patient heterogeneity explains varied response.

R Levy
PMCID: PMC2540296  PMID: 8019288

Full text

PDF

Page 1506

1506

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byrne E. J., Arie T. Tetrahydroaminoacridine and Alzheimer's disease. BMJ. 1994 Apr 2;308(6933):868–869. doi: 10.1136/bmj.308.6933.868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eagger S. A., Levy R., Sahakian B. J. Tacrine in Alzheimer's disease. Lancet. 1991 Apr 27;337(8748):989–992. doi: 10.1016/0140-6736(91)92656-m. [DOI] [PubMed] [Google Scholar]
  3. Farlow M., Gracon S. I., Hershey L. A., Lewis K. W., Sadowsky C. H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992 Nov 11;268(18):2523–2529. [PubMed] [Google Scholar]
  4. Levy R., Eagger S., Griffiths M., Perry E., Honavar M., Dean A., Lantos P. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet. 1994 Jan 15;343(8890):176–176. doi: 10.1016/s0140-6736(94)90966-0. [DOI] [PubMed] [Google Scholar]
  5. Maltby N., Broe G. A., Creasey H., Jorm A. F., Christensen H., Brooks W. S. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. BMJ. 1994 Apr 2;308(6933):879–883. doi: 10.1136/bmj.308.6933.879. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES